Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
treprostinil + iloprost
- Development stage
- Unknown
- Lead developer
- United Therapeutics
- Modality
- Small Molecules
- Administration
- Inhalation
01
Overview
Treprostinil-Iloprost SMI is an investigational, fixed-dose combination inhaled therapy being developed by United Therapeutics Corporation. It combines two synthetic prostacyclin analogues, treprostinil and iloprost, delivered as an inhalation spray via a soft mist inhaler (SMI). The therapy is designed for pro re nata (as-needed) use to provide episodic symptom relief for patients with pulmonary arterial hypertension (PAH) who experience acute symptom flare-ups between scheduled doses of their maintenance prostacyclin therapy. Both components act as agonists of the prostacyclin (IP) receptor, promoting vasodilation of the pulmonary arterial vasculature. In October 2026, the US FDA cleared the Investigational New Drug (IND) application for a Phase 1 clinical trial to evaluate the safety, tolerability, and pharmacokinetics of the combination in healthy volunteers, with a Phase 2 trial in PAH patients anticipated to begin in 2027.
- Other names
- Treprostinil-Iloprost SMItreprostinil/iloprost
02
Targets
PTGDR (Prostanoid DP1 receptor)PTGER1 (Prostaglandin E Receptor 1)PTGER2 (Prostaglandin E2 receptor EP2)PTGIR (Prostanoid IP Receptor)
Beyond the preview
Go deeper on treprostinil + iloprost.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on treprostinil + iloprost.